CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Regenerative Patch Technologies LLC |
Jane Stephanie Lebkowski |
Clinical Trial Stage Projects |
A Phase 2b, Randomized, Assessor-Masked Clinical Trial to Assess the Safety and Efficacy of the CPCB-RPE1 Implant in Subjects with Geographic Atrophy |
$12,373,748 |
| Combangio, Inc. |
R. Kim Brazzell |
Clinical Trial Stage Projects |
Phase 2b Clinical Study of KPI-012 Topical Ophthalmic Human Mesenchymal Stem Cell Secretome for the Treatment of Persistent Corneal Epithelial Defect |
$15,000,000 |
| City of Hope, Beckman Research Institute |
Dr. Angelo Manuel Almeida Cardoso Ph.D., MD |
Clinical Trial Stage Projects |
Evaluation of Safety and Feasibility of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV/HIV-CAR) T Cells in People with HIV |
$11,299,976 |
| Immusoft Corporation |
Dr Robert Hayes |
Clinical Trial Stage Projects |
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 |
$8,000,000 |
| Eureka Therapeutics, Inc. |
Pei Wang |
Clinical Trial Stage Projects |
Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer |
$10,600,072 |
| Stanford University |
Dr. Matthew H Porteus |
Clinical Trial Stage Projects |
Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients |
$10,642,420 |
| Genascence Corporation |
Dr. Thomas W Chalberg Jr. |
Clinical Trial Stage Projects |
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA |
$11,637,194 |
| City of Hope, Beckman Research Institute |
Ryotaro Nakamura |
Clinical Trial Stage Projects |
Treatment of Severe Aplastic Anemia by induction of mixed chimerism using CD4+ T cell depleted haploidentical donor stem cell transplant |
$9,054,216 |
| Stanford University |
Alice Bertaina |
Clinical Trial Stage Projects |
Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant |
$11,998,188 |
| Neurona Therapeutics |
Dr. Cory R Nicholas |
Clinical Trial Stage Projects |
Phase 1/2 Study of NRTX-1001 Neural Cell Therapy in Subjects with Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy |
$7,999,999 |
| Excision BioTherapeutics |
Mr. Daniel Dornbusch |
Clinical Trial Stage Projects |
Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy |
$4,940,000 |
| City of Hope, Beckman Research Institute |
Dr Jana Portnow |
Clinical Trial Stage Projects |
A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas |
$11,999,984 |
| Stanford University |
Dr. Rosa Bacchetta |
Clinical Trial Stage Projects |
Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome |
$11,999,179 |
| University of California, Davis |
Peter C Belafsky |
Clinical Trial Stage Projects |
A Double-Blind Randomized Placebo-Controlled Investigation of Autologous Muscle Derived Progenitor Cells for the Treatment of Dysphagia |
$11,015,936 |
| BioEclipse Therapeutics INC. |
Dr. Pamela Reilly Contag PhD |
Clinical Trial Stage Projects |
PHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS |
$7,999,689 |
| Stanford University |
Crystal Mackall |
Clinical Trial Stage Projects |
Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma |
$11,998,310 |
| Stanford University |
Dr. Joseph C. Wu |
Clinical Trial Stage Projects |
A Phase I, Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes in PaTients with ChrOnic Ischemic Left VentRicular Dysfunction (HECTOR) |
$6,987,507 |
| Stanford University |
Dr. Matthew H Porteus |
Clinical Trial Stage Projects |
Phase 1/1b study of T-allo10 infusion after HLA-partially matched abdepleted-HSCT in children and young adults with hematologic malignancies. |
$10,563,822 |
| Cedars-Sinai Medical Center |
Professor Clive Niels Svendsen |
Clinical Trial Stage Projects |
CNS10-NPC-GDNF delivered into the motor cortex for the treatment of ALS |
$11,990,372 |
| Stanford University |
Dr. Gary Steinberg |
Clinical Trial Stage Projects |
Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects with Chronic Ischemic Subcortical Stroke |
$11,998,988 |
| City of Hope, Beckman Research Institute |
Dr. Leo D Wang |
Clinical Trial Stage Projects |
Phase I Study of IL13Rα2-Targeting CAR T Cells After Lymphodepletion for Children with Refractory or Recurrent Malignant Brain Tumors |
$8,401,309 |
| University of California, San Francisco |
Steven G. Deeks |
Clinical Trial Stage Projects |
Anti-HIV duoCAR-T cell therapy for HIV infection |
$8,970,732 |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Clinical Trial Stage Projects |
Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency |
$10,301,486 |
| City of Hope, Beckman Research Institute |
Dr Jana Portnow |
Clinical Trial Stage Projects |
A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$7,961,042 |
| Cedars-Sinai Medical Center |
Professor Clive Niels Svendsen |
Clinical Trial Stage Projects |
Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$6,354,477 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Clinical Trial Stage Projects |
Phase 1/2 study for autologous human CD34+ hematopoietic stem cells ex vivo transduced with pCCL-CTNS lentiviral vector for treatment of Cystinosis. |
$11,999,944 |
| University of California, San Francisco |
Peter Stock |
Clinical Trial Stage Projects |
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM |
$7,913,768 |
| Stanford University |
Dr. Everett H. Meyer |
Clinical Trial Stage Projects |
Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients |
$8,920,000 |
| Stanford University |
Robert Lowsky |
Clinical Trial Stage Projects |
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
| Cure Rare Disease |
Dr. Susan Perlman |
Late Stage Preclinical Projects |
Advancing a novel antisense oligonucleotide for the treatment of SCA3, a devastating neurodegenerative disease |
$5,692,538 |
| University of California, Davis |
Dr. Joseph S Anderson |
Late Stage Preclinical Projects |
Expression of Ube3a by the hematopoietic system for the treatment of Angelman syndrome |
$4,487,656 |
| Rejuvenate Bio |
Noah Davidsohn |
Late Stage Preclinical Projects |
Novel Gene Therapy Targeting Multiple Pathological Drivers of Desmoplakin Associated Arrhythmogenic Cardiomyopathy |
$570,000 |
| Amplo Biotechnology |
Patricio Sepulveda |
Late Stage Preclinical Projects |
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes |
$2,894,305 |
| University of California, San Diego |
Mark H Tuszynski |
Late Stage Preclinical Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,000,000 |
| University of California, Los Angeles |
Arjun Deb |
Late Stage Preclinical Projects |
Development of a therapeutic monoclonal antibody for the treatment of myocardial infarction and heart failure |
$5,999,998 |
| Children’s Hospital of Los Angeles |
Shahab Asgharzadeh |
Late Stage Preclinical Projects |
Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors |
$6,000,000 |
| University of California, San Francisco |
Thomas Martin |
Late Stage Preclinical Projects |
A 1XX-enhanced and fully non-viral BCMA CAR T cell therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1) |
$4,585,501 |
| Elpida Therapeutics |
Mr Terry Pirovolakis |
Late Stage Preclinical Projects |
Pre-Clinical To Clinical Gene Therapy Development For CMT4J |
$3,930,964 |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Late Stage Preclinical Projects |
Neural stem cell delivered CRAd-S-pk7 oncolytic viro-immunotherapy for ovarian cancer |
$5,314,547 |
| Mahzi Therapeutics |
Dr. Yael Weiss |
Late Stage Preclinical Projects |
Development of a Gene Therapy for the Treatment of WWOX related epileptic encephalopathy (WOREE) |
$4,000,000 |
| University of California, Davis |
Dr Mehrdad Abedi |
Late Stage Preclinical Projects |
Superior forward-oriented b-globin vector for treating Sickle Cell Disease |
$4,598,398 |
| University of Southern California |
Mark Salman Humayun |
Late Stage Preclinical Projects |
IND-enabling program for PRPE-SF, the secretome from polarized stem cell-derived RPE cells, for the treatment of dry-age related macular degeneration |
$5,993,562 |
| University of California, Irvine |
Kyriacos A Athanasiou |
Late Stage Preclinical Projects |
Treatment of the TMJ disc complex |
$6,000,000 |
| Stanford University |
Dr. Matthew H Porteus |
Late Stage Preclinical Projects |
Autologous Gene Corrected Sinus Basal Cells to Treat Serious Cystic Fibrosis Sinus Disease |
$6,000,000 |
| Ossium Health, Inc. |
Dr. Brian Johnstone |
Late Stage Preclinical Projects |
Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease |
$3,457,858 |
| University of California, Davis |
Dr. Joseph S Anderson |
Late Stage Preclinical Projects |
Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease |
$3,998,253 |
| University of California, San Francisco |
Dr. Karin Lindgren Gaensler |
Late Stage Preclinical Projects |
Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells |
$6,000,000 |
| ImmunoVec |
Dr. Ryan L. Wong |
Late Stage Preclinical Projects |
Hematopoietic Stem Cell Gene Therapy for XCGD |
$3,999,959 |
| University of California, Los Angeles |
Dr. Antoni Ribas MD/PhD |
Late Stage Preclinical Projects |
Skin regeneration and wound healing with a topical BRAF inhibitor |
$5,005,126 |
